AstraZeneca to buy Actavis lung drugs as fourth quarter earnings fall short

AstraZeneca said on Thursday it had agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial payment of $600 million (£394.74 million) as it seeks external deals to ensure growth. Core earnings per share, however, are forecast to increase by a low single-digit percent this year.